Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Farmers Insurance
Daiichi Sankyo
Express Scripts
Harvard Business School
Cerilliant
Fish and Richardson
Queensland Health
Cantor Fitzgerald
Baxter

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021336

« Back to Dashboard
NDA 021336 describes EMSAM, which is a drug marketed by Somerset and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the EMSAM profile page.

The generic ingredient in EMSAM is selegiline. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the selegiline profile page.

Summary for NDA: 021336

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:3
Therapeutic Class:Antidepressants
Formulation / Manufacturing:see details

Pharmacology for NDA: 021336

Suppliers and Packaging for NDA: 021336

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL 021336 NDA Mylan Specialty L.P. 49502-900 49502-900-05 5 POUCH in 1 CARTON (49502-900-05) > 1 PATCH in 1 POUCH (49502-900-11) > 24 h in 1 PATCH
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL 021336 NDA Mylan Specialty L.P. 49502-900 49502-900-30 30 POUCH in 1 CARTON (49502-900-30) > 1 PATCH in 1 POUCH (49502-900-01) > 24 h in 1 PATCH

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength6MG/24HR
Approval Date:Feb 27, 2006TE:RLD:Yes
Patent:► SubscribePatent Expiration:May 10, 2018Product Flag?YSubstance Flag?YDelist Request?
Patent:► SubscribePatent Expiration:Jun 12, 2018Product Flag?YSubstance Flag?YDelist Request?
Patent:► SubscribePatent Expiration:May 10, 2018Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 021336

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-001Feb 27, 2006► Subscribe► Subscribe
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-002Feb 27, 2006► Subscribe► Subscribe
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-003Feb 27, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Dow
Colorcon
Baxter
Healthtrust
Federal Trade Commission
Chinese Patent Office
Cerilliant
Fish and Richardson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot